Loading company…
OncoLab develops immune-oncology treatments for hard-to-treat cancers.
OncoLab develops cancer therapeutics using its ANGel platform, which combines antibodies and nanogels to support drug delivery. Founded in 2024, the company is based in Cheongju, South Korea, and targets hard-to-treat cancers including triple-negative breast cancer. In November 2025, it raised KRW 1 billion in pre-Series A funding from FuturePlay to support clinical trials and product development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in